Schedule of data collection
| Items | Screening period within 1 week | Treatment period 1–6 months | Follow-up period 7–12 months |
| Signed informed consent | √ | ||
| Inclusion/exclusion criteria | √ | ||
| Demographic data | √ | ||
| Medical history, course of disease, treatment history | √ | ||
| Combined diseases | √ | ||
| Concomitant medications | √ | √ | |
| Plaque characteristics | √ | √ | |
| Blood lipid indicators | √ | √ | |
| Efficacy of angina symptoms | √ | √ | |
| SAQ | √ | √ | |
| MACEs | √ | ||
| hs-CRP | √ | √ | |
| Vital signs | √ | √ | |
| Blood, urine and stool routine | √ | √ | |
| Liver and kidney function | √ | √ | |
| Adverse events | √ | √ | |
| eCRF examination | √ |
Vital signs: temperature, heart rates, breathing and blood pressure.
√represents the indicators tested in the specific time period.
CRP, C-reactive protein; eCRF, electronic case report form; MACE, major adverse cardiac event; SAQ, Seattle Angina Questionnaire.